US2011076270A1PendingUtilityA1

Therapeutic Binding Molecules

46
Assignee: NOVARTIS AGPriority: Sep 18, 2003Filed: Jun 30, 2010Published: Mar 31, 2011
Est. expirySep 18, 2023(expired)· nominal 20-yr term from priority
Inventors:Gregorio AversaFrank KolbingerJose M. Carballido HerreraAndreás AszódiJose SaldanhaBruce M. Hall
A61P 37/02C07K 2317/74A61P 37/00C07K 2317/565C07K 16/289A61K 2039/505C07K 2317/24C07K 2317/92C07K 2317/75C07K 2317/73C07K 2317/56C07K 2317/41
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A molecule comprising at least one antigen binding site, comprising in sequence the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1′, CDR2′ and CDR3′, CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a pharmaceutical.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody or functional fragment thereof which binds CD45RB/CD45RO comprising the polypeptide of SEQ ID NO:8 and the polypeptide of SEQ ID NO: 31. 
     
     
         2 . An isolated antibody or functional fragment thereof which binds CD45RB/CD45RO comprising:
 a) a first domain comprising the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH) (SEQ ID NO:22), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) (SEQ ID NO:23) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT) (SEQ ID NO:24); and   b) a second domain comprising the hypervariable regions CDR1′, CDR2′ and CDR3′, said CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ) (SEQ ID NO:19), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) (SEQ ID NO:20) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT) (SEQ ID NO:21).   
     
     
         3 . The isolated antibody according to  claim 2 , which is a chimeric or humanised monoclonal antibody. 
     
     
         4 . The isolated antibody or functional fragment thereof according to  claim 2 , comprising a polypeptide of SEQ ID NO: 31. 
     
     
         5 . The isolated antibody or functional fragment thereof according to  claim 2 , comprising a polypeptide of SEQ ID NO:8. 
     
     
         6 . The isolated antibody according to  claim 4  which is a chimeric monoclonal antibody. 
     
     
         7 . An isolated antibody or functional fragment thereof which binds CD45RB/CD45RO which is a humanised antibody comprising a polypeptide of SEQ ID NO:8 and a polypeptide of SEQ ID NO: 31. 
     
     
         8 . A pharmaceutical composition comprising the isolated antibody or functional fragment thereof according to  claim 1  in association with at least one pharmaceutically acceptable carrier or diluent. 
     
     
         9 . A pharmaceutical composition comprising the isolated antibody or functional fragment thereof according to  claim 2  in association with at least one pharmaceutically acceptable carrier or diluent. 
     
     
         10 . The isolated antibody according to  claim 1 , which is a chimeric or humanised monoclonal antibody. 
     
     
         11 . An isolated antibody or functional fragment thereof which binds CD45RB/CD45RO comprising a polypeptide of SEQ ID NO: 31. 
     
     
         12 . The isolated antibody according to  claim 11 , which is a chimeric or humanised monoclonal antibody. 
     
     
         13 . A pharmaceutical composition comprising the isolated antibody or functional fragment thereof according to  claim 11 , in association with at least one pharmaceutically acceptable carrier or diluent. 
     
     
         14 . An isolated F(ab′) 2  or Fab fragment which binds CD45RB/CD45RO comprising the polypeptide of SEQ ID NO:8 and the polypeptide of SEQ ID NO: 31. 
     
     
         15 . An isolated F(ab′) 2  or Fab fragment which binds CD45RB/CD45RO comprising:
 a) a first domain comprising the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence Asn-Tyr-Ile-Ile-His (NYIIH) (SEQ ID NO:22), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) (SEQ ID NO:23) and said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT) (SEQ ID NO:24); and 
 b) a second domain comprising the hypervariable regions CDR1′, CDR2′ and CDR3′, said CDR1′ having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ) (SEQ ID NO:19), CDR2′ having the amino acid sequence Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) (SEQ ID NO:20) and CDR3′ having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT) (SEQ ID NO:21). 
 
     
     
         16 . The isolated F(ab′) 2  or Fab fragment according to  claim 15 , comprising a polypeptide of SEQ ID NO: 31. 
     
     
         17 . The isolated F(ab′) 2  or Fab fragment according to  claim 15 , comprising a polypeptide of SEQ ID NO:8. 
     
     
         18 . A pharmaceutical composition comprising the isolated F(ab′) 2  or Fab fragment according to  claim 14  in association with at least one pharmaceutically acceptable carrier or diluent.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.